drugset / Trial / NCT00486408

Expanded Characterization of Immune Response to Merck Adenovirus 5 Gag/Pol/Nef Vaccine Given to HIV Uninfected Adults

NCT00486408 ↗

Non-randomizedSingle-groupOpen-labelPrevention

Summary

The purpose of this study is to intensively characterize the immune response, particularly the T-cell response, to a three-dose regimen of an adenovirus-based HIV-1 vaccine in HIV-uninfected adults.

Timeline

Start
2007-07
Primary completion
2008-09
Completion
2012-11

Drugs

EvaluationDrugModalityDoseRoute
Subject MRKAd5 HIV-1 gag/pol/nef Vaccine 1.5e+10 vg Intramuscular